Fabrice Barlési

Research interests

Publications

• Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2310532

• Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.04.005

• IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.09.014

• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.06.017

• Sotorasib for Lung Cancers with KRAS p.G12C Mutation

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2103695

• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30314-4

• Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

  Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.11.025

• Caring for patients with cancer in the COVID-19 era

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0874-8

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005651

• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.014

• KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917239

• Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.010

• Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

  Cell · 2020 · https://doi.org/10.1016/j.cell.2020.08.002

• Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30690-4

• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

  The Lancet Respiratory Medicine · 2019 · 10.1016/s2213-2600(19)30084-0

• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

  The Lancet Respiratory Medicine · 2019 · 10.1016/s2213-2600(19)30084-0

• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz167

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910231

• Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30673-9

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

• Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1716948

• Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

  Journal of Thoracic Oncology · 2018 · https://doi.org/10.1016/j.jtho.2018.05.030

• Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.71.7629

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.74.3062

• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw326

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32517-x

• Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30146-2

• Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1507643

• Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-14-2082

• Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.42.3749

• Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.6095

• Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.9782

Current projects

No projects listed.